“For the rules to be changed after the game has started to be played is a bit un-American,” Mr. Saunders said in the interview, according to the report.
On April 4, the U.S. Treasury Department issued regulations that would make tax inversions less lucrative for companies.
Mr. Saunders stressed that the deal seems to only have a direct effect on the Pfizer-Allergan deal. “I don’t believe, based on an initial review, it impacts any other deal in virtually any other circumstance,” he said, according to The Hill.
However, White House press secretary Josh Earnest claimed targeting the Pfizer-Allergan transaction was not the Treasury’s aim, according to the report.
More articles on leadership and management:
Glenn Medical Center, EmCare form partnership: 5 things to know
Is NEJM’s reputation slipping? 5 things to know
Regional Medical Center to cut 33 positions: 5 things to know
